nach oben

Journal of Cardiovascular Translational Research

Erschienen in:

01.02.2014

Impact of Aspirin Dosing on the Effects of P2Y₁₂ Inhibition in Patients with Acute Coronary Syndromes

verfasst von: Mark R. Thomas, Robert F. Storey

Erschienen in: Journal of Cardiovascular Translational Research | Ausgabe 1/2014

Einloggen, um Zugang zu erhalten

Abstract

The discovery of the antiplatelet effect of low-dose aspirin led to the hugely successful strategy of dual antiplatelet therapy in patients with acute coronary syndromes (ACS). Increasing the dose of aspirin beyond 75–100 mg has never been shown to offer additional efficacy in ACS patients but could possibly increase the risk of bleeding. In the Platelet Inhibition and Patients Outcome (PLATO) study, higher doses of aspirin appeared to neutralise the additional benefit of the potent P2Y₁₂ inhibitor ticagrelor compared to clopidogrel (Circulation 124: 544–554, 2011). However, higher doses of aspirin have not been shown to have an adverse interaction with the potent P2Y₁₂ inhibition provided by prasugrel and double-dose clopidogrel (Journal of the American College of Cardiology, 2013, in press; N Engl J Med 363: 930–942, 2010). This potentially suggests that the mechanism for this interaction is not related to the inhibition of platelet P2Y₁₂ receptors or could simply be a chance finding.

Mahaffey, K. W., Wojdyla, D. M. D., Carroll, K. K., Becker, R. C., Storey, R. F., Angiolillo, D. J., et al. (2011). Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation, 124, 544–554.PubMedCrossRef

Kohli, P., Udell, J.A. Murphy, S.A., Cannon, C.P., Antman, E.M., Braunwald, E., Wiviott. S.D. (2013). Discharge Aspirin Dose and Clinical Outcomes in Patients with Acute Coronary Syndromes treated with Prasugrel vs. Clopidogrel: An Analysis from the TRITON-TIMI 38 Study. Journal of the American College of Cardiology ; in press.

CURRENT-OASIS 7 Investigators, Mehta, S. R., Bassand, J.-P., Chrolavicius, S., Diaz, R., Eikelboom, J. W., et al. (2010). Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. New England Journal of Medicine, 363, 930–942.PubMedCrossRef

ISIS-2 (Second International Study of Infarct Survival) Collaborative Group 1. (1988). Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. The Lancet, 2, 349–360.

Warner, T. D., Armstrong, P. C. J., Curzen, N. P., & Mitchell, J. A. (2010). Dual antiplatelet therapy in cardiovascular disease: does aspirin increase clinical risk in the presence of potent P2Y12 receptor antagonists? Heart, 96, 1693–1694.PubMedCrossRef

Maclagan, T. ( 1876). The treatment of rheumatism by salicin and salicylic acid. BMJ BMJ Group;1: 627.

Vane, J. R., & Botting, R. M. (2003). The mechanism of action of aspirin. Thrombosis Research, 110, 255–258.PubMedCrossRef

Patrono, C., García-Rodríguez, L. A., Landolfi, R., & Baigent, C. (2005). Low-dose aspirin for the prevention of atherothrombosis. New England Journal of Medicine, 353, 2373–2383.PubMedCrossRef

Roth, G. J., Stanford, N., & Majerus, P. W. (1975). Acetylation of prostaglandin synthase by aspirin. Proc Natl Acad Sci USA National Acad Sciences, 72, 3073–3076.CrossRef

10.

Hamberg, M., Svensson, J., & Samuelsson, B. (1974). Letter: mechanism of the anti-aggregating effect of aspirin on human platelets. The Lancet, 2, 223–224.CrossRef

11.

Pinckard, R. N., Hawkins, D., & Farr, R. S. (1968). In vitro acetylation of plasma proteins, enzymes and DNA by aspirin. Nature, 219, 68–69.PubMedCrossRef

12.

Rocca, B., Secchiero, P., Ciabattoni, G., Ranelletti, F. O., Catani, L., Guidotti, L., et al. (2002). Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets. Proc Natl Acad Sci USA National Acad Sciences, 99, 7634–7639.CrossRef

13.

FitzGerald, G. A., Oates, J. A., Hawiger, J., Maas, R. L., Roberts, L. J., Lawson, J. A., et al. (1983). Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. Journal of Clinical Investigation, 71, 676–688.PubMedCentralPubMedCrossRef

14.

Pedersen, A. K., & FitzGerald, G. A. (1984). Dose-related kinetics of aspirin. New England Journal of Medicine, 311, 1206–1211.PubMedCrossRef

15.

Bochner, F., Williams, D. B., Morris, P. M., Siebert, D. M., & Lloyd, J. V. (1988). Pharmacokinetics of low-dose oral modified release, soluble and intravenous aspirin in man, and effects on platelet function. European Journal of Clinical Pharmacology, 35, 287–294.PubMedCrossRef

16.

Thiessen, J. J. J. (1983). Aspirin: plasma concentration and effects. Thrombosis Research, 4, 105–111.CrossRef

17.

Jaffe, E. A., & Weksler, B. B. (1979). Recovery of endothelial cell prostacyclin production after inhibition by low doses of aspirin. Journal of Clinical Investigation, 63, 532–535.PubMedCentralPubMedCrossRef

18.

Mehta, J. L., Mehta, P., Lopez, L., Ostrowski, N., & Aguila, E. (1984). Platelet function and biosynthesis of prostacyclin and thromboxane A2 in whole blood after aspirin administration in human subjects. Journal of the American College of Cardiology, 4, 806–811.PubMedCrossRef

19.

Weksler, B. B., Pett, S. B., Alonso, D., Richter, R. C., Stelzer, P., Subramanian, V., et al. (1983). Differential inhibition by aspirin of vascular and platelet prostaglandin synthesis in atherosclerotic patients. N Engl J Med Massachusetts Medical Society, 308, 800–805.CrossRef

20.

De Caterina, R., Giannessi, D., Bernini, W., Gazzetti, P., Michelassi, C., L'abbate, A., et al. (1985). Selective inhibition of thromboxane-related platelet function by low-dose aspirin in patients after myocardial infarction. The American Journal of Cardiology, 55, 589–590.PubMedCrossRef

21.

Hanley, S. P., Bevan, J., Cockbill, S. R., & Heptinstall, S. (1981). Differential inhibition by low-dose aspirin of human venous prostacyclin synthesis and platelet thromboxane synthesis. The Lancet, 1, 969–971.CrossRef

22.

Patrignani, P., Filabozzi, P., & Patrono, C. (1982). Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. Journal of Clinical Investigation, 69, 1366–1372.PubMedCentralPubMedCrossRef

23.

Patrono, C., Ciabattoni, G., Patrignani, P., Pugliese, F., Filabozzi, P., Catella, F., et al. (1985). Clinical pharmacology of platelet cyclooxygenase inhibition. Circulation, 72, 1177–1184.PubMedCrossRef

24.

Belton, O., Byrne, D., Kearney, D., Leahy, A., & Fitzgerald, D. J. (2000). Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis. Circulation, 102, 840–845.PubMedCrossRef

25.

Schrör, K. (1990). Thromboxane A2 and platelets as mediators of coronary arterial vasoconstriction in myocardial ischaemia. European Heart Journal, 11(Suppl B), 27–34.PubMedCrossRef

26.

FitzGerald, G. A. (1991). Mechanisms of platelet activation: thromboxane A 2 as an amplifying signal for other agonists. The American Journal of Cardiology Elsevier, 68, B11–B15.CrossRef

27.

Weiss, H. J., Aledort, L. M., & Kochwa, S. (1968). The effect of salicylates on the hemostatic properties of platelets in man. Journal of Clinical Investigation, 47, 2169–2180.PubMedCentralPubMedCrossRef

28.

Evans, G., Packham, M. A., Nishizawa, E. E., Mustard, J. F., & Murphy, E. A. (1968). The effect of acetylsalicylic acid on platelet function. J Exp Med Rockefeller Univ Press, 128, 877–894.

29.

Masotti, G., Poggesi, L., Galanti, G., Abbate, R., & Serneri, G. G. N. (1979). Differential inhibition of prostacyclin production and platelet aggregation by aspirin. The Lancet Elsevier, 314, 1213–1216.CrossRef

30.

Taylor, M. L., Misso, N. L., Stewart, G. A., & Thompson, P. J. (1992). The effects of varying doses of aspirin on human platelet activation induced by PAF, collagen and arachidonic acid. British Journal of Clinical Pharmacology, 33, 25–31.PubMedCentralPubMedCrossRef

31.

Moshfegh, K. K., Redondo, M. M., Julmy, F. F., Wuillemin, W. A. W., Gebauer, M. U. M., Haeberli, A. A., et al. (2000). Antiplatelet effects of clopidogrel compared with aspirin after myocardial infarction: enhanced inhibitory effects of combination therapy. Journal of the American College of Cardiology, 36, 7–7.CrossRef

32.

Dabaghi, S. F., Kamat, S. G., Payne, J., Marks, G. F., Roberts, R., Schafer, A. I., et al. (1994). Effects of low-dose aspirin on in vitro platelet aggregation in the early minutes after ingestion in normal subjects. The American Journal of Cardiology, 74, 720–723.PubMedCrossRef

33.

Capodanno, D., Patel, A., Dharmashankar, K., Ferreiro, J. L., Ueno, M., Kodali, M., et al. (2011). Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease. Circulation. Cardiovascular Interventions, 4, 180–187.PubMedCrossRef

34.

Pope, J. E., Anderson, J. J., & Felson, D. T. (1993). A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Archives of Internal Medicine, 153, 477–484.PubMedCrossRef

35.

Grosser, T., Fries, S., & FitzGerald, G. A. (2006). Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest Am Soc Clin Investig, 116, 4–15.CrossRef

36.

Guazzi, M.D., Campodonico, J., Celeste, F., Guazzi, M., Santambrogio G, Rossi M, Trabattoni D, Alimento M. Antihypertensive efficacy of angiotensin converting enzyme inhibition and aspirin counteraction. Clinical Pharmacology & Therapeutics 63: 79–86.

37.

Schwartz, K. A., Schwartz, D. E., Ghosheh, K., Reeves, M. J., Barber, K., & DeFranco, A. (2005). Compliance as a critical consideration in patients who appear to be resistant to aspirin after healing of myocardial infarction. The American Journal of Cardiology, 95, 973–975.PubMedCrossRef

38.

Rocca, B., Santilli, F., Pitocco, D., Mucci, L., Petrucci, G., Vitacolonna, E., et al. (2012). The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes. Journal of Thrombosis and Haemostasis, 10, 1220–1230.PubMedCrossRef

39.

Reilly, I. A., & FitzGerald, G. A. (1987). Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood, 69, 180–186.PubMed

40.

Armstrong, P. C. J., Truss, N. J., Ali, F. Y., Dhanji, A.-R. A., Vojnovic, I., Zain, Z. N. M., et al. (2008). Aspirin and the in vitro linear relationship between thromboxane A2-mediated platelet aggregation and platelet production of thromboxane A2. Journal of Thrombosis and Haemostasis, 6, 1933–1943.PubMedCrossRef

41.

Aradi, D., Storey, R.F., Komócsi, A., Trenk, D., Gulba, D., Kiss R.G., Husted, S., Bonello L., Sibbing, D., Collet. J.-P., Huber, K. (2013). on behalf of the Working Group on Thrombosis of the European Society of Cardiology. Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention. European Heart Journal . doi: 10.1093/eurheartj/eht375.

42.

Kong, D. F. D., Hasselblad, V. V., Kandzari, D. E. D., Newby, L. K. L., & Califf, R. M. R. (2002). Seeking the optimal aspirin dose in acute coronary syndromes. The American Journal of Cardiology, 90, 622–625.PubMedCrossRef

43.

Antithrombotic Trialists' Collaboration. (2002). Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ, 324, 71–86.CrossRef

44.

McQuaid, K. R., & Laine, L. (2006). Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials. The American Journal of Medicine Elsevier, 119, 624–638.CrossRef

45.

Storey, R. F., Sanderson, H. M., White, A. E., May, J. A., Cameron, K. E., & Heptinstall, S. (2000). The central role of the P(2 T) receptor in amplification of human platelet activation, aggregation, secretion and procoagulant activity. British Journal of Haematology, 110, 925–934.PubMedCrossRef

46.

Storey, R. F., Angiolillo, D. J., Patil, S. B., Desai, B., Ecob, R., Husted, S., et al. (2010). Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes. Journal of the American College of Cardiology, 56, 1456–1462.PubMedCrossRef

47.

Michelson, A. D., Frelinger, A. L., Braunwald, E., Downey, W. E., Angiolillo, D. J., Xenopoulos, N. P., et al. (2009). For the TRITON-TIMI 38 Investigators. Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial. European Heart Journal, 30, 1753–1763.PubMedCrossRef

48.

Hamm, C. W., Bassand, J.-P., Agewall, S., Bax, J., Boersma, E., Bueno, H., et al. (2011). ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the task force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). European Heart Journal, 32, 2999–3054.PubMedCrossRef

49.

Jneid, H., Anderson, J. L., Wright, R. S., Adams, C. D., Bridges, C. R., Casey, D. E., et al. (2012). 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation, 126, 875–910.PubMedCrossRef

50.

Yusuf, S., Zhao, F., Mehta, S. R., Chrolavicius, S., Tognoni, G., & Fox, K. K. (2001). Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. New England Journal of Medicine, 345, 494–502.PubMedCrossRef

51.

Peters, R.J.G., Mehta, S.R., Fox, K.A.A., Zhao, F., Lewis, B.S., Kopecky, S.L., Diaz, R., Commerford, P.J., Valentin, V., Yusuf, S. (2003). Investigators CIUATPRECT. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation, 108, 1682–1687.

52.

van Giezen, J. J. J., Sidaway, J., Glaves, P., Kirk, I., & Bjorkman, J. A. (2012). Ticagrelor inhibits adenosine uptake in vitro and enhances adenosine-mediated hyperemia responses in a canine model. Journal of Cardiovascular Pharmacology and Therapeutics, 17, 164–172.PubMedCrossRef

53.

Wallentin, L., Becker, R. C., Budaj, A., Cannon, C. P., Emanuelsson, H., Held, C., et al. (2009). Ticagrelor versus clopidogrel in patients with acute coronary syndromes. New England Journal of Medicine, 361, 1045–1057.PubMedCrossRef

54.

Cattaneo, M. M., & Lecchi, A. A. (2007). Inhibition of the platelet P2Y12 receptor for adenosine diphosphate potentiates the antiplatelet effect of prostacyclin. Journal of Thrombosis and Haemostasis, 5, 577–582.PubMedCrossRef

55.

Teng, R., Maya, J., & Butler, K. (2013). Evaluation of the pharmacokinetics and pharmacodynamics of ticagrelor co-administered with aspirin in healthy volunteers. Platelets, 24(8), 615–624.PubMedCentralPubMedCrossRef

56.

Varenhorst, C., Alstrom, U., Scirica, B. M., Hogue, C. W., Åsenblad, N., Storey, R. F., et al. (2012). Factors contributing to the lower mortality with ticagrelor compared with clopidogrel in patients undergoing coronary artery bypass surgery. Journal of the American College of Cardiology, 60, 1623–1630.PubMedCrossRef

57.

Storey RF, James SK, Siegbahn A, Varenhorst C, Held C, Ycas J, Husted SE, Cannon CP, Becker RC, Steg PG, Åsenblad N, Wallentin L. Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO study. Platelets 2013; doi:10.3109/09537104.2013.842965.

58.

Grzesk, G. G., Kozinski, M. M., Navarese, E. P. E., Krzyzanowski, M. M., Grzesk, E. E., Kubica, A. A., et al. (2012). Ticagrelor, but not clopidogrel and prasugrel, prevents ADP-induced vascular smooth muscle cell contraction: a placebo-controlled study in rats. Thrombosis Research, 130, 65–69.PubMedCrossRef

59.

Högberg, C., Svensson, H., Gustafsson, R., Eyjolfsson, A., & Erlinge, D. (2010). The reversible oral P2Y12 antagonist AZD6140 inhibits ADP-induced contractions in murine and human vasculature. International Journal of Cardiology, 142, 187–192.PubMedCrossRef

60.

Grzesk, G., Kozinski, M., Tantry, U. S., Wicinski, M., Fabiszak, T., Navarese, E. P., et al. (2013). High-dose, but not low-dose, aspirin impairs anticontractile effect of ticagrelor following ADP stimulation in rat tail artery smooth muscle cells. Biomed Res Int, 2013, 928271.PubMedCentralPubMedCrossRef

61.

Wiviott, S. D., Braunwald, E., McCabe, C. H., Montalescot, G., Ruzyllo, W., Gottlieb, S., et al. (2007). Prasugrel versus clopidogrel in patients with acute coronary syndromes. New England Journal of Medicine, 357, 2001–2015.PubMedCrossRef

62.

Warner, T. D., Nylander, S., & Whatling, C. (2011). Anti‐platelet therapy: cyclo‐oxygenase inhibition and the use of aspirin with particular regard to dual anti‐platelet therapy. Br J Clin Pharmacol Wiley Online Library; 72, 619–633.CrossRef

63.

Iyú, D. D., Glenn, J. R. J., White, A. E. A., Fox, S. C. S., van Giezen, H. H., Nylander, S. S., et al. (2011). Mode of action of P2Y(12) antagonists as inhibitors of platelet function. Thrombosis and Haemostasis, 105, 96–106.PubMedCrossRef

64.

Armstrong, P. C. J. P., Leadbeater, P. D. P., Chan, M. V. M., Kirkby, N. S. N., Jakubowski, J. A. J., Mitchell, J. A. J., et al. (2011). In the presence of strong P2Y12 receptor blockade, aspirin provides little additional inhibition of platelet aggregation. Journal of Thrombosis and Haemostasis, 9, 552–561.PubMedCentralPubMedCrossRef

65.

Kirkby, N. S. N., Leadbeater, P. D. M. P., Chan, M. V. M., Nylander, S. S., Mitchell, J. A. J., & Warner, T. D. T. (2011). Antiplatelet effects of aspirin vary with level of P2Y₁₂ receptor blockade supplied by either ticagrelor or prasugrel. Journal of Thrombosis and Haemostasis, 9, 2103–2105.PubMedCentralPubMedCrossRef

66.

Dewilde, W. J., Oirbans, T., Verheugt, F. W., Kelder, J. C., De Smet, B. J., Herrman, J.-P., et al. (2013). Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. The Lancet, 381, 1107–1115.CrossRef

67.

Eikelboom, J. W., Mehta, S. R., Anand, S. S., Xie, C., Fox, K. A. A., & Yusuf, S. (2006). Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation, 114, 774–782.PubMedCrossRef

68.

Hurlen, M., Abdelnoor, M., Smith, P., Erikssen, J., & Arnesen, H. (2002). Warfarin, aspirin, or both after myocardial infarction. N Engl J Med Mass Medical Soc, 347, 969–974.CrossRef

69.

Wallentin, L. C. (1991). Aspirin (75 mg/day) after an episode of unstable coronary artery disease: long-term effects on the risk for myocardial infarction, occurrence of severe angina and the need for revascularization. Research Group on Instability in Coronary Artery Disease in Southeast Sweden. Journal of the American College of Cardiology, 18, 1587–1593.PubMedCrossRef

Titel: Impact of Aspirin Dosing on the Effects of P2Y12 Inhibition in Patients with Acute Coronary Syndromes
verfasst von: Mark R. Thomas
Robert F. Storey
Publikationsdatum: 01.02.2014
Verlag: Springer US
Erschienen in: Journal of Cardiovascular Translational Research / Ausgabe 1/2014
Print ISSN: 1937-5387
Elektronische ISSN: 1937-5395
DOI: https://doi.org/10.1007/s12265-013-9524-6

Neu im Fachgebiet Kardiologie

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 Adipositas Nachrichten

Der als Antidiabetikum sowie zum Gewichtsmanagement zugelassene Wirkstoff Tirzepatid hat in Studien bei adipösen Patienten auch schlafbezogene Atmungsstörungen deutlich reduziert, informiert der Hersteller in einer Vorab-Meldung zum Studienausgang.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2014

Scientific Foundation and Possible Implications for Practice of the Minimizing Adverse Haemorrhagic Events by Transradial Access Site and Systemic Implementation of AngioX (MATRIX) Trial

Impact of Cigarette Smoking on P2Y12 Receptor Binding Activity Before and After Clopidogrel Therapy in Patients with Coronary Artery Disease

Gender and Anti-thrombotic Therapy: from Biology to Clinical Implications

Antiplatelet Therapy: Targeting the TxA2 Pathway